US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCENTAGE PHARMA GROUP

41.82

-0.6500-1.53%

Volume:13.98K

Turnover:586.46K

Market Cap:3.89B

PE:-56.86

High:42.47

Open:41.95

Low:41.36

Close:42.47

52wk High:48.45

52wk Low:16.50

Shares:92.96M

Float Shares:71.58M

Volume Ratio:1.19

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7356

EPS(LYR):-0.7356

ROE:-159.65%

ROA:-22.77%

PB:41.71

PE(LYR):-56.86

Loading ...

Overview Company News Filings

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025

CICC Maintains Outperform Rating on ASCENTAGE-B (06855), Raises Target Price to HK$105

Ascentage Pharma Swings to H1 Loss, Revenue Falls

MT Newswires Live

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

ASCENTAGE-B (06855) Reports Interim Results with RMB 234 Million in Revenue; Nerlynx® (Olverembatinib) China Sales Surge 93% Year-over-Year

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

MT Newswires Live

Ascentage Pharma Receives US, EU Approvals for Study of Potential Myelodysplastic Syndrome Treatment

MT Newswires Live

Hong Kong's "Tech Duo" Rise in Tandem! Hong Kong Stock Connect Innovative Pharma ETF (520880) Gains Over 2%, ASCENTAGE PHARMA GROUP Surges 9% to Record High

Hong Kong Stock Movement | ASCENTAGE-B (06855) Opens Up Over 4% After Lisaftoclax Phase III Clinical Study for Intermediate-to-High Risk MDS Receives FDA and EMA Approval

Ascentage Pharma receives clearance from U.S. FDA, EMA to conduct GLORA-4

ASCENTAGE-B (06855): Lestauva® Global Phase III Clinical Trial for First-Line Treatment of Intermediate-High Risk MDS Patients Receives Approval from US FDA and European EMA

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

J.P. Morgan Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG)

Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025

Ascentage Pharma Group International : JP Morgan Raises Target Price to $46 From $27

THOMSON REUTERS

Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025

Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement

Hong Kong Stock Movement | Ascentage Pharma (06855.HK) Surges Over 4% in Morning Session After Raising HK$1.5B Via Placement to Accelerate Commercialization and Drug Pipeline Development

Ascentage Pharma (06855) Gains Over 4% Pre-Market on HK$1.49B Share Placement to Fuel Commercialization and R&D

Ascentage Pharma Prices 22 Million Share Placement

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AAPG/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"ASCENTAGE PHARMA GROUP","latestPrice":41.82,"timestamp":1756843200000,"preClose":42.47,"halted":0,"volume":13984,"delay":0,"floatShares":71582800,"shares":92963368,"eps":-0.735552,"marketStatus":"Pre-Mkt","change":-0.65,"latestTime":"09-03 07:19:34 EDT","open":41.95,"high":42.47,"low":41.3613,"amount":586462.9741,"amplitude":0.026105,"askPrice":42.88,"askSize":200,"bidPrice":41.14,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1756906200000},"marketStatusCode":1,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":41.795,"postHourTrading":{"tag":"盘后","latestPrice":41.82,"preClose":41.82,"latestTime":"17:45 EDT","volume":103,"amount":4237.735,"timestamp":1756849519753},"volumeRatio":1.1879860256103116},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":1.1879860256103116,"shares":92963368,"dividePrice":0,"high":42.47,"amplitude":0.026105,"preClose":42.47,"low":41.3613,"week52Low":16.5,"pbRate":"41.71","psRate":"71.12","week52High":48.45,"institutionHeld":0,"latestPrice":41.82,"eps":-0.735552,"divideRate":0,"volume":13984,"delay":0,"ttmEps":-0.735552,"open":41.95,"prevYearClose":17.25,"prevWeekClose":42.47,"prevMonthClose":42.47,"prevQuarterClose":39.375,"fiveDayClose":43.48,"twentyDayClose":37.6,"sixtyDayClose":27.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"Pre-Market","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2025-08-29","current":-24.396919,"percent":0.986486,"low":-76.454813,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"high":-23.707409,"avg":-43.114344,"sd":13.979917,"marketCap":3966417985.85},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85}],"updateTime":1756861714979},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562249756","title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2562249756","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562249756?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:00","pubTimestamp":1756123200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Aug.  25, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/25/3138401/0/en/Ascentage-Pharma-to-Participate-in-Three-Upcoming-Investor-Conferences-in-September-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"1192193476","title":"CICC Maintains Outperform Rating on ASCENTAGE-B (06855), Raises Target Price to HK$105","url":"https://stock-news.laohu8.com/highlight/detail?id=1192193476","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192193476?lang=en_us&edition=fundamental","pubTime":"2025-08-25 10:48","pubTimestamp":1756090105,"startTime":"0","endTime":"0","summary":"CICC issued a research report maintaining its 2025/2026 net profit attributable to shareholders forecasts for ASCENTAGE-B (06855) unchanged, while keeping its outperform rating. Considering the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1161","AAPG","BK1574","06855"],"gpt_icon":0},{"id":"2561450553","title":"Ascentage Pharma Swings to H1 Loss, Revenue Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2561450553","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561450553?lang=en_us&edition=fundamental","pubTime":"2025-08-21 16:57","pubTimestamp":1755766657,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International  reported an H1 loss late Wednesday of 1.73 Chinese renminbi  per diluted share, compared with earnings of 0.55 renminbi a year earlier.Revenue for the half-year ended June 30 was 233.7 million renminbi, down from 823.7 million renminbi a year earlier.Analysts' estimates were not readily available for comparison.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AAPG"],"gpt_icon":0},{"id":"2561387994","title":"Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2561387994","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561387994?lang=en_us&edition=fundamental","pubTime":"2025-08-21 07:57","pubTimestamp":1755734220,"startTime":"0","endTime":"0","summary":"Product sales from Olverembatinib in the first half of 2025 increased93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverageCommenced commerc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/20/3136791/0/en/Ascentage-Pharma-Reports-2025-Interim-Unaudited-Six-Months-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","LU0942090050.USD","LU1430594728.SGD","LU1778281490.HKD","LU2237443465.HKD","LU1235294995.USD","LU2237443895.HKD","BK4527","LU0868494708.USD","IE00BVYPNW00.USD","LU0234572021.USD","LU0823417737.USD","DTP","BK4020","LU1571399168.USD","LU2462157665.USD","BK4581","LU2237443622.USD","BK4534","IE00B42XCP33.USD","LU1880398554.USD","BK4560","LU1599440770.SGD","IE00BFMHRM44.USD","BK4515","BK4550","BK4533","BK4203","LU1880398471.USD","IE00BGHQF631.EUR","HR","LU1032955483.USD","LU1823568750.SGD","LU1267930813.SGD","LU1046421795.USD","LU1894683348.USD","SG9999001424.SGD","IE00BDGV0183.EUR","SG9999001440.SGD","SG9999015978.USD","CSCO","IE00BKVL7J92.USD","LU2237443978.SGD","AAPG","LU1059921491.USD","BK4612","LU1674673428.USD","LU1883839398.USD","LU1196500208.SGD","LU1066051811.HKD"],"gpt_icon":0},{"id":"1119779824","title":"ASCENTAGE-B (06855) Reports Interim Results with RMB 234 Million in Revenue; Nerlynx® (Olverembatinib) China Sales Surge 93% Year-over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1119779824","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119779824?lang=en_us&edition=fundamental","pubTime":"2025-08-21 07:34","pubTimestamp":1755732851,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 234 million. Sales of Nerlynx® (olverembatinib) in China increased by RMB 105...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","06855","BK1574","BK1161","AAPG"],"gpt_icon":0},{"id":"2560597188","title":"Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2560597188","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560597188?lang=en_us&edition=fundamental","pubTime":"2025-08-18 21:10","pubTimestamp":1755522616,"startTime":"0","endTime":"0","summary":"Health care stocks were flat to higher pre-bell Monday, with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) up 0.3%.Novo Nordisk (NVO) shares were up ne","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4583","BK4585","IE00BZ1G4Q59.USD","XLV","IE00BKVL7J92.USD","NVO","BK7104","BK4532","LU1093756168.USD","BK4581","AAPG","BK4007","IBB","LU1093756325.SGD","BK4599","LU0154236417.USD","TNXP","BK4139","BK4588","NVO.AU"],"gpt_icon":0},{"id":"2560977436","title":"Ascentage Pharma Receives US, EU Approvals for Study of Potential Myelodysplastic Syndrome Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2560977436","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560977436?lang=en_us&edition=fundamental","pubTime":"2025-08-18 16:22","pubTimestamp":1755505355,"startTime":"0","endTime":"0","summary":"Ascentage Pharma (AAPG) said Sunday it has received clearance from the US Food and Drug Administration and the European Medicines Agency to conduct a phase 3 study of its drug lisaftoclax in combinati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4156","AAPG"],"gpt_icon":0},{"id":"1196068016","title":"Hong Kong's \"Tech Duo\" Rise in Tandem! Hong Kong Stock Connect Innovative Pharma ETF (520880) Gains Over 2%, ASCENTAGE PHARMA GROUP Surges 9% to Record High","url":"https://stock-news.laohu8.com/highlight/detail?id=1196068016","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196068016?lang=en_us&edition=fundamental","pubTime":"2025-08-18 10:22","pubTimestamp":1755483753,"startTime":"0","endTime":"0","summary":"On August 18, Hong Kong stocks opened higher in early trading, with Hong Kong's tech duo - technology/internet and innovative pharmaceuticals - once again strengthening together. As of press time,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSTECH","BK4614","07226","YANG","BK4139","AAPG","HSCEI","515120","159741"],"gpt_icon":1},{"id":"1186043890","title":"Hong Kong Stock Movement | ASCENTAGE-B (06855) Opens Up Over 4% After Lisaftoclax Phase III Clinical Study for Intermediate-to-High Risk MDS Receives FDA and EMA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1186043890","media":"Stock News","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186043890?lang=en_us&edition=fundamental","pubTime":"2025-08-18 09:28","pubTimestamp":1755480527,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) opened up over 4%. As of press time, it rose 4.53% to HK$90, hitting a record high with a trading volume of HK$16.893 million. On the news front, ASCENTAGE PHARMA GROUP announced...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","EMA","BK4139","III","BK4134","BK1161","AAPG","BK4081"],"gpt_icon":0},{"id":"2560597329","title":"Ascentage Pharma receives clearance from U.S. FDA, EMA to conduct GLORA-4","url":"https://stock-news.laohu8.com/highlight/detail?id=2560597329","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560597329?lang=en_us&edition=fundamental","pubTime":"2025-08-18 09:15","pubTimestamp":1755479704,"startTime":"0","endTime":"0","summary":"Ascentage Pharma (AAPG) announced that it has received clearance by the U.S. Food and Drug Administration, FDA, and the European Medicines Agency, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-receives-clearance-from-u-s-fda-ema-to-conduct-glora-4-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-receives-clearance-from-u-s-fda-ema-to-conduct-glora-4-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAPG","BK4139","EMA","BK4081"],"gpt_icon":0},{"id":"1137833130","title":"ASCENTAGE-B (06855): Lestauva® Global Phase III Clinical Trial for First-Line Treatment of Intermediate-High Risk MDS Patients Receives Approval from US FDA and European EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=1137833130","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137833130?lang=en_us&edition=fundamental","pubTime":"2025-08-18 07:38","pubTimestamp":1755473912,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) announced that the company's self-developed Bcl-2 selective inhibitor lisaftoclax (trade name: Lestauva®; development code: APG-2575) in combination with azacitidine (AZA) for...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK1161","III","BK1574","06855","BK4134","AAPG","BK4081","BK4139"],"gpt_icon":0},{"id":"2560978307","title":"Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2560978307","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560978307?lang=en_us&edition=fundamental","pubTime":"2025-08-18 07:30","pubTimestamp":1755473400,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Aug.  17, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the disco","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/17/3134672/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Lisaftoclax-for-First-line-Treatment-of-Patients-with-Higher-Risk-Myelodysplastic-Syndrome-Cleared-by-US-FDA-and.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","ORR","BK4109","BK4139","HMA","EMA","BK4161","BK4081","LU2463526074.USD","BK4134","ASH","CR","III"],"gpt_icon":0},{"id":"2557524565","title":"J.P. Morgan Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2557524565","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557524565?lang=en_us&edition=fundamental","pubTime":"2025-08-08 20:19","pubTimestamp":1754655588,"startTime":"0","endTime":"0","summary":"In a report released on August 6, Brian Cheng from J.P. Morgan maintained a Buy rating on Ascentage Pharma Group International Unsponsored ADR, wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-ascentage-pharma-group-international-unsponsored-adr-aapg-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-ascentage-pharma-group-international-unsponsored-adr-aapg-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAPG"],"gpt_icon":0},{"id":"2557565414","title":"Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2557565414","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557565414?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:00","pubTimestamp":1754568000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Aug.  07, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129154/0/en/Ascentage-Pharma-to-Report-2025-Six-Month-Interim-Results-and-Provide-Corporate-Update-on-August-20-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2557374452","title":"Ascentage Pharma Group International : JP Morgan Raises Target Price to $46 From $27","url":"https://stock-news.laohu8.com/highlight/detail?id=2557374452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557374452?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:26","pubTimestamp":1754483160,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY1W2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06855","BK1574","BK4139","AAPG","BK1161"],"gpt_icon":0},{"id":"2553488772","title":"Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2553488772","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553488772?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:00","pubTimestamp":1753272000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, July  23, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/23/3120184/0/en/Ascentage-Pharma-to-Participate-in-BTIG-Virtual-Biotechnology-Conference-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2552510449","title":"Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2552510449","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552510449?lang=en_us&edition=fundamental","pubTime":"2025-07-17 16:30","pubTimestamp":1752741000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, July  17, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/17/3117028/0/en/Ascentage-Pharma-Announces-Closing-of-Placement-Shares-in-Top-Up-Placement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"1132843807","title":"Hong Kong Stock Movement | Ascentage Pharma (06855.HK) Surges Over 4% in Morning Session After Raising HK$1.5B Via Placement to Accelerate Commercialization and Drug Pipeline Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1132843807","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132843807?lang=en_us&edition=fundamental","pubTime":"2025-07-16 12:30","pubTimestamp":1752640247,"startTime":"0","endTime":"0","summary":"Ascentage Pharma (06855.HK) jumped over 4% during Monday's morning trading, climbing 4.11% to HK$74.75 with turnover reaching HK$495 million. The biopharmaceutical firm recently announced plans to...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK1161","06855","BK4139","159992","BK1574","06978"],"gpt_icon":0},{"id":"1144938295","title":"Ascentage Pharma (06855) Gains Over 4% Pre-Market on HK$1.49B Share Placement to Fuel Commercialization and R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1144938295","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144938295?lang=en_us&edition=fundamental","pubTime":"2025-07-16 11:58","pubTimestamp":1752638309,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group (06855) surged more than 4% during morning trading, rising 4.11% to HK$74.75 by midday with a turnover reaching HK$495 million. This momentum follows the company's announcement...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","06978","AAPG","159992","BK1161","BK1574","BK4139"],"gpt_icon":0},{"id":"2551187659","title":"Ascentage Pharma Prices 22 Million Share Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2551187659","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551187659?lang=en_us&edition=fundamental","pubTime":"2025-07-14 23:07","pubTimestamp":1752505674,"startTime":"0","endTime":"0","summary":"Ascentage Pharma  said Monday it priced an offering of 22 million common shares at HK$68.60  per share.The shares are being sold by a trust affiliated with Chief Executive Dajun Yang in an offshore placement outside the US, raising around HK$1.51 billion. The offering was oversubscribed by 8 times and is expected to close Thursday.After the placement closes, the trust will reinvest by subscribing to 22 million new shares at the same price.The proceeds will be used to support commercialization and patient access efforts, global clinical trials for key drug candidates, infrastructure improvements, and working capital, the company said.Shares of Ascentage Pharma fell past 4% in recent trading activity.Price: 36.64, Change: -1.60, Percent Change: -4.18","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AAPG"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}